An observational study in Psoriasis, sponsored by Amgen. Completed at 1 site in Japan. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Amgen · Observational
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica
Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey.
- Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey.
Exclusion Criteria:
Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets
Adverse Events (AEs)
Number of participants with adverse events
Time frame: Up to approximately 12 months
General Improvement Rating
General Improvement Rating will be assessed by physician's observation
Time frame: Approximately 1 year from administration
General health assessment on VAS
Visual Analog Scale (VAS) pain will be used for psoriatic arthritis patients' assessment.
Time frame: Approximately 1 year from administration
Changes in physician general assessment
PGA: assessment for psoriatic vulgaris by physician to classify disease activity in a consistent manner
Time frame: Approximately 1 year from administration
Percentage of patients with Dermatology Life Quality Index (DLQI)
The Dermatology Life Quality Index or DLQI is a dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire
Time frame: Approximately 1 year from administration
Change from baseline activity for arthritis
Activity for arthritis Baseline is calculated by Disease Activity Score-DAS28 method
Time frame: Approximately 1 year from administration
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Sap, Icf, Csr
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amgen